09:11 AM EST, 12/17/2025 (MT Newswires) -- Cytokinetics ( CYTK ) said Wednesday its investigational therapy Myqorzo has been approved by the China National Medical Products Administration for the treatment of adults with New York Heart Association class II-III obstructive hypertrophic cardiomyopathy, to improve exercise capacity and symptoms.

The approval triggers a $7.5 million milestone payment from Sanofi ( SNY ) under a license and collaboration agreement, as Sanofi ( SNY ) has exclusive rights to develop and commercialize Myqorzo for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy in Greater China, Cytokinetics ( CYTK ) said.

Cytokinetics ( CYTK ) said it remains eligible to receive up to $142.5 million in development and commercial milestone payments from Sanofi ( SNY ) as well as royalties in the low-to-high teens on future sales of Myqorzo in Greater China.

Shares of Cytokinetics ( CYTK ) were more than 3% higher in premarket trading.